Peptides represent a billion-dollar market in the pharmaceutical industry, but they can generally only be taken as injections to avoid degradation by stomach enzymes. Scientists at EPFL have now developed a method to generate peptides that resist enzymatic degradation and can be taken orally.
Peptides are short chains of amino acids that occur in our body, in plants or bacteria to control diverse functions. Several peptides are used as drugs such as insulin, which controls the metabolism of sugar, and cyclosporine, which suppresses organ rejection after transplants. More than 40 peptides are already approved as drugs, generating revenues in the billions. There are several hundreds of peptide-based medications currently in clinical trials.
But almost none of these drug-peptides can be taken orally. Since peptides are an important part of food, the stomach and intestines harbor countless enzymes that can degrade them, meaning that most peptide-based medication do not survive the passage through the gastrointestinal tract.
Hope to generate more stable peptides came from “cyclic” peptides, whose ends are joined together by chemical bridges making them more stable than linear ones because their backbones are less flexible and thus harder to attack by enzymes. In 2018, the research group of Christian Heinis at EPFL developed a peptide format termed double-bridged peptides, where peptides are cyclized by two chemical bridges that provide even higher stability. Despite its success, most such peptides were not sufficiently stable to survive the enormous enzymatic pressure found in the gastrointestinal tract.
Now, Heinis’s group has developed a new method that identifies among billions of double-bridged peptides those that bind a disease target of interest and survive enzymes of the gastrointestinal tract. The method is published in Nature Biomedical Engineering, and involves three steps.
First, billions of genetically encoded random peptide sequences are cyclized by two chemical bridges that impose conformational constraints onto the peptides’ backbones so that they are more difficult to attack by enzymes.
Second, this library of peptides is exposed to enzymes from cow intestine to eliminate all those peptides that are not stable.
In the third and last step, the scientist dip target proteins into the pool of surviving peptides to fish out those that bind to the wanted disease target. “It’s a bit like searching a needle in a haystack, and this method makes this easy,” says Heinis.
With this method, the researchers have succeeded for the first time in evolving target-specific peptides that can resist breakdown in the gastrointestinal tract. For example, they gave mice a lead peptide that inhibits thrombin – an important anti-thrombosis target – in the form of a pill. The peptide remained intact in the stomach and intestines, and even though it reached the blood stream in rather small quantities, most of it remained fully intact across the entire gastrointestinal tract. This is a key step towards engineering oral peptide drugs.
Heinis’s group is now applying the new method to develop oral peptides that act directly on gastrointestinal targets, meaning that they don’t need to travel into the blood stream. “We are focusing on chronic inflammatory diseases of the gastrointestinal tract like Crohn’s disease and ulcerative colitis as well as bacterial infections,” says Heinis. “We have already succeeded in generating enzyme-resistant peptides against the interleukin-23 receptor, an important target of these diseases, which affect millions of patients worldwide without any oral drug available.”
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
- Novo Nordisk (NVO) to Begin Study on Oral Semaglutide in Obesityon April 22, 2021 at 8:37 pm
The study will evaluate the safety and efficacy of oral semaglutide versus placebo in approximately 1,000 people with obesity or overweight with comorbidities. Please note that, Ozempic (semaglutide) ...
- Melphalan Flufenamide Emerges as Option for Heavily Pretreated Myelomaon April 22, 2021 at 7:04 am
Joseph Mikhael, MD, MEd, FRCPC, FACP, discussed how melphalan flufenamide could potentially shift the treatment paradigm for patients with multiple myeloma.
- Global Oral Proteins and Peptides Market 2020 Remarking Enormous Growth with Recent Trends & Demandon April 21, 2021 at 2:04 am
New York, NY The report on global Oral Proteins and Peptides Market offers in-depth analysis of major market players, revenue, market share, market segments & its sub segments, and geographic regions.
- UK Peptide Drugs Market 2021 Key Players, Industry Size, Share, Segmentation, Comprehensive Analysis and Forecast by 2027on April 20, 2021 at 12:17 am
AI Market Report is working on a new report title Global Peptide Drugs Market: Global Size, Trends, Competitive, ...
- Intranasal Third-Generation CGRP Effective for Acute Migraineon April 18, 2021 at 5:00 pm
Intranasal zavegepant, a third-generation calcitonin gene-related peptide receptor agonist, is effective and well tolerated in the treatment of acute migraine, new research shows.
Go deeper with Google Headlines on:
Go deeper with Bing News on:
- Can SARS-CoV-2 host factor protein interactions help identify antiviral drug targets?on April 22, 2021 at 10:36 am
In a new study proteomic peptide-phage display is utilized to profile the novel SLiM-based interactions that mediate host factor interactions in 229 RNA viruses, with a special focus on SARS-CoV-2, to ...
- ISSAR Pharma to license its peptide-based new chemical entitieson April 19, 2021 at 3:47 am
The firm, which has over 25 years of R&D experience, has the capability to synthesise custom peptides, API peptides and cosmetic peptides.
- Qilu Pharmaceutical and Peptron Sign License Agreement for anti-MUC1 ADCon April 16, 2021 at 7:04 am
PAb001-ADC is a pre-clinical ADC entering into Investigational New Drug ("IND") enabling studies ... to develop patient-friendly, peptide-based medicines with a high technological entrance ...
- ISSAR Pharma Announces Out-Licensing of Its Peptide-Based NCEson April 16, 2021 at 2:59 am
ISSAR Pharmaceuticals, the Pioneer in Peptide Technology and peptide drug innovation, has decided to license out their peptide-based New Chemical Entities (NCEs), with pre-IND filing and US Patent.
- With a New Diabetes Product Coming to Market, What Lies Ahead for Zealand Pharma Investors?on April 12, 2021 at 1:23 pm
A new, easier-to-administer treatment for severe hypoglycemia has observers and investors wondering where its creators will go next.